menu
    • menu
    [{"orgOrder":0,"company":"Generium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Dornase Alfa","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Generium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Generium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Generium \/ Undisclosed"},{"orgOrder":0,"company":"Generium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"RUSSIA","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Dornase Alfa","moa":"DNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Generium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Generium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Generium \/ Undisclosed"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2011","type":"Inapplicable","leadProduct":"Dornase Alfa","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Georgetown University \/ Genentech","highestDevelopmentStatusID":"11","companyTruncated":"Georgetown University \/ Genentech"},{"orgOrder":0,"company":"University of Illinois, Chicago","sponsor":"Genentech | National Eye Institute","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"Dornase Alfa","moa":"DNA","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"University of Illinois, Chicago","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of Illinois, Chicago \/ Genentech | National Eye Institute","highestDevelopmentStatusID":"7","companyTruncated":"University of Illinois, Chicago \/ Genentech | National Eye Institute"},{"orgOrder":0,"company":"McGill University Health Centre Research Institute","sponsor":"Hamilton Health Sciences | F. Hoffmann-La Roche | Exactis Innovation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Dornase Alfa","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"McGill University Health Centre Research Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McGill University Health Centre Research Institute \/ Hamilton Health Sciences | F. Hoffmann-La Roche | Exactis Innovation","highestDevelopmentStatusID":"6","companyTruncated":"McGill University Health Centre Research Institute \/ Hamilton Health Sciences | F. Hoffmann-La Roche | Exactis Innovation"},{"orgOrder":0,"company":"Hershey Medical Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Dornase Alfa","moa":"DNA","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Hershey Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Hershey Medical Center \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"Hershey Medical Center \/ Genentech"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2012","type":"Inapplicable","leadProduct":"Dornase Alfa","moa":"DNA","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Genentech \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Dornase Alfa

    Menu

    Dornase Alfa

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Generium

                            Russia arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Generium

                            Russia arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dornase Alfa

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis

                            Details : Tigerase (Dornase Alfa) is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cystic Fibrosis.

                            Product Name : Tigerase

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            July 13, 2020

                            Lead Product(s) : Dornase Alfa

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Generium

                            Russia arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Generium

                            Russia arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dornase Alfa

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19

                            Details : Dornase Alfa is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            July 07, 2020

                            Lead Product(s) : Dornase Alfa

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            McGill University Health Centre Research Institute

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            McGill University Health Centre Research Institute

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dornase Alfa

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Hamilton Health Sciences | F. Hoffmann-La Roche | Exactis Innovation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1)

                            Details : Dornase Alfa is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            June 01, 2020

                            Lead Product(s) : Dornase Alfa

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Hamilton Health Sciences | F. Hoffmann-La Roche | Exactis Innovation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            University of Illinois, Chicago

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            University of Illinois, Chicago

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dornase Alfa

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Genentech | National Eye Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease

                            Details : Dornase Alfa is a Enzyme drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Graft vs Host Disease.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            March 08, 2016

                            Lead Product(s) : Dornase Alfa

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Genentech | National Eye Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Genentech

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Genentech

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dornase Alfa

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer Sy...

                            Details : Dornase Alfa is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cystic Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            October 23, 2012

                            Lead Product(s) : Dornase Alfa

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Georgetown University

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Georgetown University

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dornase Alfa

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Genentech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dornase Alfa Therapy for Ventilator Associated Lung Infections in the Neonatal Intensive Care Unit (NICU)

                            Details : Dornase Alfa is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Respiratory Tract Infections.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            May 19, 2011

                            Lead Product(s) : Dornase Alfa

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Genentech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Hershey Medical Center

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Hershey Medical Center

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dornase Alfa

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase III

                            Sponsor : Genentech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pulmozyme in Cystic Fibrosis With Sinusitis

                            Details : Dornase Alfa is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Sinusitis.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            July 02, 2010

                            Lead Product(s) : Dornase Alfa

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase III

                            Sponsor : Genentech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth